The best HGH peptides are the ones whose mechanism and evidence fit a specific clinical question. Sermorelin, tesamorelin, CJC-1295, and ipamorelin do not supply human growth hormone, so none is HGH itself. They are secretagogues: signals that prompt a functioning pituitary to release endogenous growth hormone. Sermorelin is the simplest short-acting GHRH analogue; tesamorelin has the deepest indication-specific human evidence; CJC-1295 changes substantially depending on whether it includes DAC; and ipamorelin activates a second receptor. Best therefore means best-fit, never strongest.
What best means for HGH peptides
There are two receptor families in this comparison. Sermorelin, tesamorelin, and CJC-1295 are analogues of growth hormone-releasing hormone, or GHRH. They bind the GHRH receptor on pituitary somatotroph cells. Ipamorelin is a growth hormone secretagogue that binds GHS-R1a, better known as the ghrelin receptor. Both pathways can end in a growth hormone pulse, but they start with different signals.
That upstream action is the key distinction from exogenous HGH. A secretagogue asks the pituitary to release hormone; HGH supplies the hormone directly and bypasses that step. A functioning pituitary and the body's feedback signals therefore remain relevant with these peptides. The deeper comparison between a releasing peptide and direct hormone therapy belongs in sermorelin versus HGH.
This also explains why a higher laboratory number does not automatically identify a better option. Baseline IGF-1, age, glucose regulation, pituitary function, cancer history, goals, and the evidence for the proposed use all affect fit. A prescriber should be matching a mechanism to a person, not selecting the peptide with the most aggressive online description.
Best HGH peptides compared at a glance
Half-life is useful, but formulation matters. In particular, the multi-day CJC-1295 numbers come from the DAC form, which binds albumin. They should not be assigned to CJC-1295 without DAC.
| Peptide | Receptor and mechanism | Human half-life evidence | What it was studied in | When a prescriber might consider it |
|---|---|---|---|---|
| Sermorelin | GHRH analogue; GHRH receptor | Minutes; GHRH(1-29) had a 4.3-minute disappearance half-time during IV infusion | Historical pediatric growth-hormone deficiency treatment and pituitary testing | A short-acting, single-pathway GHRH option when the pituitary can respond |
| Tesamorelin | Stabilized GHRH analogue; GHRH receptor | About 11 minutes after a subcutaneous dose of the current branded formulation | HIV-associated lipodystrophy with excess abdominal fat | The question closely matches its unusually specific and substantial human trial record |
| CJC-1295 | Modified GHRH analogue; GHRH receptor | Form-dependent: short-acting without DAC; 5.8–8.1 days with DAC in a human study | Small healthy-adult endocrine studies, principally of the DAC form | A GHRH signal within a two-receptor blend, after confirming which form is prescribed |
| Ipamorelin | GHS/GHS-R1a agonist; ghrelin receptor | About 2 hours in healthy male volunteers | Early human pharmacology and unsuccessful postoperative-ileus development | A second receptor signal, usually considered as part of a combination rather than as a GHRH analogue |
The table is a map, not a prescribing ladder. The 4.3-minute sermorelin figure came from a constant-infusion study of ten healthy men (Soule et al., Journal of Clinical Endocrinology & Metabolism 1994). The current tesamorelin half-life and indication come from the 2025 EGRIFTA WR label. Different routes and formulations make a direct minute-for-minute potency inference inappropriate.
Why CJC-1295 and ipamorelin are paired
A combination can pair one signal from each receptor family: CJC-1295 at the GHRH receptor and ipamorelin at the ghrelin receptor. Older human physiology work found that submaximal GHRH and a growth hormone-releasing peptide produced a synergistic acute GH response in 18 healthy men, supporting the idea that the pathways act independently (Bowers et al., Journal of Clinical Endocrinology & Metabolism 1990). That is a class-level mechanism result, not a clinical outcome trial of today's compounded blend.
Formulation is the practical catch. In two small randomized studies, CJC-1295 with DAC had a measured 5.8–8.1-day half-life and raised mean GH for at least six days and IGF-1 for 9–11 days in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006). Promise's paired formulation uses CJC-1295 without DAC, so those duration numbers do not describe that vial. Ipamorelin separately had an approximately two-hour terminal half-life in healthy-volunteer infusion research (Gobburu et al., Pharmaceutical Research 1999).
For pairwise detail, see sermorelin versus CJC-1295 and sermorelin versus ipamorelin.
Tesamorelin has the strongest narrow evidence base
Tesamorelin stands apart because its major trials measured a clinical body-composition endpoint in a defined population. In a 404-person randomized trial of adults with HIV and excess abdominal fat, visceral adipose tissue decreased 10.9% after six months with tesamorelin versus 0.6% with placebo; participants who continued for 12 months had an approximately 18% reduction (Falutz et al., Journal of Acquired Immune Deficiency Syndromes 2010). Those results belong to HIV-associated lipodystrophy. They do not establish general weight-loss, anti-aging, or athletic outcomes.
That narrowness is a feature of good comparison, not a weakness to conceal. The FDA label says the branded tesamorelin product is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy and is not indicated for weight-loss management. Promise's tesamorelin is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
Sermorelin has a different regulatory history. Current compounded sermorelin is not FDA-approved. Earlier Geref products were approved for pediatric idiopathic growth-hormone deficiency and for pituitary testing, then discontinued at the manufacturer's request; their approvals were withdrawn effective June 18, 2009. FDA later determined that the withdrawals were not for safety or effectiveness reasons (Federal Register, March 4, 2013). The old approval cannot be transferred to a current compounded preparation. Tesamorelin versus sermorelin examines that evidence gap directly.
What a prescriber weighs before choosing
A useful review starts with the proposed clinical reason and asks whether human evidence exists in a comparable population. It then checks whether the pituitary axis can respond and whether raising GH and IGF-1 creates avoidable risk. Active malignancy, some pituitary disorders, pregnancy, glucose dysregulation, medication interactions, and elevated IGF-1 can materially change the answer. The exact caution set differs by compound; tesamorelin's branded label, for example, contraindicates active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis.
Monitoring is part of the choice. A clinician may consider baseline and follow-up IGF-1 and glucose markers, symptoms such as fluid retention or joint discomfort, and whether there is any measurable benefit tied to the original goal. A peptide's short plasma half-life does not remove the need for follow-up, because downstream signaling can outlast the molecule itself.
FDA review status is one input, not a marketing gate. A licensed provider may still prescribe a compounded formulation when appropriate, and that decision is between the patient and the doctor. The honest best-fit answer may also be none of these.
At Promise, a licensed provider reviews every request and prescribes only when the chosen option is medically appropriate; not everyone qualifies. If prescribed, the formulation is prepared and dispensed by a licensed U.S. compounding pharmacy, and the prescriber sets the dose, timing, monitoring, and duration.